Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome

Journal of Pathology

Volumn 202, Issue 2, 2004, Pages 145-156

  Bhatia, Madhav ^a   Moochhala, Shabbir ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Defence Medical Research Institute   (Singapore)

Author keywords

Acute respiratory distress syndrome; Chemokines; Cytokines; Leukocytes; Multiple organ dysfunction syndrome; Systemic inflammatory response syndrome

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; ANTITHROMBIN; CHEMOKINE; COMPLEMENT COMPONENT C5A; DIURETIC AGENT; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBUPROFEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; KERATINOCYTE GROWTH FACTOR; KETOCONAZOLE; LEUKOCYTE ELASTASE INHIBITOR; LISOFYLLINE; NITRIC OXIDE; PENTOXIFYLLINE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN G; PROSTAGLANDIN H; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; SUBSTANCE P; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE DISEASE; ANTIINFLAMMATORY ACTIVITY; CAUSE OF DEATH; GENE THERAPY; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY DISTRESS SYNDROME; REVIEW;

CHEMOKINES; HUMANS; INFLAMMATION MEDIATORS; MULTIPLE ORGAN FAILURE; REACTIVE OXYGEN SPECIES; RESPIRATORY DISTRESS SYNDROME, ADULT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 1142299409     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1491     Document Type: Review

References (166)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420: 885-891.
2. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001; 29: S109-S116.
3. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000; 26: S64-S74.
4. Ashbaugh DG, Bigelow DB, Petty JL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2: 319-323.
5. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824.
6. Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Annu Rev Med 2001; 52: 221-237.
7. Tasaka S, Hasegawa N, Ishizaka A. Pharmacology of acute lung injury. Pulm Pharmacol Ther 2002; 15: 83-95.
8. Bhatia M, Brady M, Shokuhi S, et al. Inflammatory mediators in acute pancreatitis. J Pathol 2000; 190: 117-125.
9. Bhatia M, Neoptolemos JP, Slavin J. Inflammatory mediators as therapeutic targets in acute pancreatitis. Curr Opin Invest Drugs 2001; 2: 496-501.
10. Bhatia M. Novel therapeutic targets for acute pancreatitis and associated multiple organ dysfunction syndrome. Curr Drug Targets - Infl Allergy 2002; 1: 343-351.
11. Moore FA, Moore EE. Evolving concepts in the pathogenesis of post injury multiple organ failure. Surg Clin North Am 1995; 75: 257-277.
12. Norman JG, Fink GW, Franz MG. Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression. Arch Surg 1995; 130: 966-970.
13. Putensen C, Wrigge H. Ventilator-associated systemic inflammation in acute lung injury. Intensive Care Med 2000; 26: 1411-1413.
14. Okusawa S, Gelfand JA, Ikejima T. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumour necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162-1172.
15. Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164: 1896-1903.
16. Siler TM, Swierkosz JE, Hyers TM, et al. Immunoreactive interleukin-1 in bronchoalveolar lavage fluid of high-risk patients and patients with the adult respiratory distress syndrome. Exp Lung Res 1989; 15: 881-894.
17. Meduri GU, Kohler G, Headley S, et al. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 1995; 108: 1303-1314.
18. Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 602-611.
19. Leff JA, Bodman ME, Cho OJ, et al. Post-insult treatment with interleukin-1 receptor antagonist decreases oxidative lung injury in rats given intratracheal interleukin-1. Am J Respir Crit Care Med 1994; 150: 109-112.
20. Denis M, Guojian L, Widmer M, et al. A mouse model of lung injury induced by microbial products: implication of tumor necrosis factor. Am J Respir Cell Mol Biol 1994; 10: 658-664.
21. Opal SM, Fisher CJ Jr, Dhainau JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-1124.
22. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1342 patients. Crit Care Med 2001; 29: 503-510.
23. Nijsten NWN, Hack CE, Helle M, ten Duis HJ, Klassen HJ, Aarden LA. Interleukin-6 and its relation to the Immoral immune response and clinical response in burnt patients. Surgery 1991; 109: 761-767.
24. Borrelli E, Roux-Lombard P, Grau GE, Giardin E, Ricou B, Dayer J. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996; 24: 392-397.
25. Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich P. Induction of rat acute phase proteins by interleukin-6 in vivo. Eur J Immunol 1988; 18: 717-721.
26. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242: 237-299.
27. Leser HG, Gross C, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute phase response and reflects severity in acute pancreatitis. Gastroenterology 1991; 101: 782-785.
28. Remick DG, Bolgos GR, Siddiqui J, et al. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17: 463-467.
29. Kasama T, Strieter RM, Lukacs NW, Burdick MD. Kunkel SL. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994; 152: 3559-3569.
30. Fiorentino D, Zlotnik A, Mosmann T, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-3822.
31. Howard M, O'Garra A, Ishida H, Malefyt RD, Devries J. Biological properties of interleukin-10. J Clin Immunol 1992; 12: 239-247.
32. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin-10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-1208.
33. Smith SR, Terminelli C, Kenworthy-Bott L, Calzetta A, Donkin J. The cooperative effects of TNF-alpha and IFN-gamma are determining factors in the ability of IL-10 to protect mice from lethal endotoxemia. J Leuk Biol 1994; 55: 711-718.
34. van der Poll T, Smith SR, Swanson SW, Hack CE, Lowry SF, Moldawer LL. Effects of IL-10 on systemic inflammatory response during lethal primate endotoxemia. J Immunol 1997; 158: 1971-1975.
35. Seitz MLP, Dewald B, Towbin H, Gallati H, Baggiolini M. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol 1995; 25: 1129-1132.
36. Lo CJ, Fu M, Cryer HG. Interleukin 10 inhibits alveolar macrophage production of inflammatory mediators involved in adult respiratory distress syndrome. J Surg Res 1998; 79: 179-184.
37. Armstrong L, Milla AB. Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome. Thorax 1997; 52: 442-446.
38. Yeh FL, Shen HD, Fang RH. Deficient transforming growth factor beta and interleukin-10 responses contribute to the septic death of burned patients. Burns 2002; 28: 631-637.
39. Kusske AM, Rongione AJ, Ashley SW, McFadden DW, Reber HA. Interleukin-10 prevents death in lethal necrotizing pancreatitis in mice. Surgery 1996: 120: 284-288.
40. Inoue G. Effect of interleukin-10 (IL-10) on experimental LPS-induced acute lung injury. J Infect Chemother 2000; 6: 51-60.
41. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002; 14: 681-685.
42. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699.
43. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959-966.
44. Broekelmann T, Limper AH, Colby TV, et al. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991; 88: 6642-6646.
45. Pittet JF, Griffiths MJ, Geiser T, et al. TGF-beta is a critical mediator of acute lung injury. J Clin Invest 2001; 107: 1537-1544.
46. Shenkar R, Coulson WF, Abraham E. Anti-transforming growth factor-beta monoclonal antibodies prevent lung injury in hemorrhaged mice. Am J Respir Cell Mol Biol 1994; 11: 351-357.
47. Trapnell BC, Whitsett JA. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 2002; 64: 775-802.
48. Williams MA, White SA, Miller JJ, et al. Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J Infect Dis 1998; 177: 107-115.
49. Perry SE, Mostafa SM, Wenstone R, et al. Low plasma granulocyte-macrophage colony stimulating factor is an indicator of poor prognosis in sepsis. Intensive Care Med 2002; 28: 981-984.
50. Presneill JJ, Harris T, Stewart AG, et al. A randomized phase II trial granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166: 138-143.
51. Prescott SM, McIntyre TM, Zimmerman GA. Platelet-activating factor: a phospholipid mediator of inflammation. In Inflammation: Basic Principles and Clinical Correlates, Gallin JI, Snyderman R (eds). Lippincott Williams & Wilkins: Philadelphia, PA, 1999; 387-389.
52. Nagase T, Ishii S, Kume K, et al. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J Clin Invest 1999: 104: 1071-1076.
53. Formela LJ, Wood LM, Whittaker M, Kingsnorth AN. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg 1994; 81: 1783-1785.
54. Hofbauer B, Bhatia M, Frossard JL, Lee HS, Bhagat L, Steer ME. Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis. Gastroenterology, 1998; 115: 1238-1247.
55. Rivera JA, Werner J, Warshaw AL, Lewandrowski KB, Rattner DW, Fernandez-del Castillo C. Lexipafant fails to improve survival in severe necrotizing pancreatitis in rats. Int J Pancreatol 1998; 23: 101-106.
56. Ishii S, Kuwaki T, Nagase T, et al. Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med 1998; 187: 1779-1788.
57. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001; 48: 62-69.
58. Poeze M, Froon AH, Ramsay G, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock 2000; 14: 421-428.
59. Suputtamongkol Y. Intaranongpai S, Smith MD, et al. A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother 2000; 44: 693-696.
60. Adams DH, Nash GB. Disturbance of leucocyte circulation and adhesion to the endothelium as factors in circulatory pathway. Br J Anaesth 1996; 77: 17-31.
61. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999; 66: 876-888.
62. Giannoudis PV. Smith RM, Banks RE, et al. Stimulation of inflammatory markers after blunt trauma. Br J Surg 1998; 85: 986-990.
63. Takano H, Yanagisawa R, Ichinose T, et al. Diesel exhaust particles enhance lung injury related to bacterial endotoxin through expression of proinflammatory cytokines, chemokines, and intercellular adhesion molecule-1. Am J Respir Crit Care Med 2002; 165: 1329-1335.
64. Muller AM, Cronen C, Muller KM, Kirkpatrick CJ. Heterogeneous expression of cell adhesion molecules by endothelial cells in ARDS. J Pathol 2002; 198: 270-275.
65. Sato N, Suzuki Y, Nishio K, et al. Roles of ICAM-1 for abnormal leukocyte recruitment in the microcirculation of bleomycin-induced fibrotic lung injury. Am J Respir Crit Care Med 2000; 161: 1681-1688.
66. Bhatia M, Hofbauer B, Lee HS, Frossard JL, Steer ML. The effects of neutrophil depletion on a completely noninvasive model of acute pancreatitis-associated lung injury. Int J Pancreatol 1998; 24: 77-83.
67. Frossard JL, Saluja A, Bhagat L, et al. The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology 1999; 116: 694-701.
68. Gerard C, Gerard NP. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994; 12: 775-808.
69. Czermak B, Lents LAB, Bless NM, Schmal H, Friedl HP, Ward PA. Role of complement in in vitro and in vivo lung inflammatory reactions. J Leukoc Biol 1998; 64: 40-48.
70. Matis LA, Rollins SA. Complement-specific antibodies: designing novel anti-inflammatories. Nature Med 1995; 1: 839-842.
71. Hopken UE, Lu B, Gerard NP, Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 1996; 383: 86-89.
72. Bozic CR, Lu B, Hopken UE, Gerard C, Gerard NP. Neurogenic amplification of immune complex inflammation. Science 1996; 273: 1722-1725.
73. Ravage ZB, Gomez HF, Czermak BJ, Watkins SA, Till GO. Mediators of microvascular injury in dermal burn wounds. Inflammation 1998; 22: 619-629.
74. Czermak BJ, Sarma V, Pierson CL, et al. Protective effects of C5a blockade in sepsis. Nature Med 1999; 5: 788-792.
75. Huber-Lang M, Sarma VJ, Lu KT, et al. Role of C5a in multiorgan failure during sepsis. J Immunol 2001; 166: 1193-1199.
76. Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001; 38: 175-187.
77. Riedemann NC, Guo RF, Neff TA, et al. Increased C5a receptor expression in sepsis. J Clin Invest 2002; 110: 101-108.
78. Huber-Lang MS, Riedeman NC, Sarma JV, et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 2002; 16: 1567-1574.
79. Riedemann NC, Neff TA, Guo RF, et al. Protective effects of IL-6 blockade in sepsis are linked to reduced c5a receptor expression. J Immunol 2003: 170: 503-507.
80. Bhatia M, Saluja A, Lee H-S, Frossard J-L, Gerard C, Steer ML. Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and pancreatitis-associated lung injury. Am J Physiol 2001; 280: G974-G978.
81. Bowden JJ, Garland AM, Baluk P, et al. Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci U S A 1994; 91: 8964-8968.
82. Thurston G, Baluk P, Hirata A, McDonald DM. Permeability-related changes revealed at endothelial cell borders in inflamed venules by lectin binding. Am J Physiol 1996; 271: H2547-H2562.
83. Bhatia M, Saluja A, Hofbauer B, et al. Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis-associated lung injury. Proc Natl Acad Sci U S A 1998; 95: 4760-4765.
84. Bhatia M, Slavin J, Cao Y, et al. Preprotachykinin-A gene deletion protects mice against acute pancreatitis and associated lung injury. Am J Physiol 2003: 284: G830-G836.
85. Matos IM, Souza DG, Seabra DG, Freire-Maia L, Teixeira MM. Effects of tachykinin NK1 or PAF receptor blockade on the lung injury induced by scorpion venom in rats. Eur J Pharmacol 1999; 376: 293-300.
86. Espiritu RF, Pittet JF, Matthay MA, Goetzl EJ. Neuropeptides in pulmonary edema fluid of adult respiratory distress syndrome. Inflammation 1992; 16: 509-517.
87. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nature Rev Immunol 2002; 2: 106-115.
88. Proudfoot AE, Power CA, Rommel C, Wells TN. Strategies for chemokine antagonists as therapeutics. Semin Immunol 2003; 15: 57-65.
89. Weber C. Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. J Mol Med 2003; 81: 4-19.
90. Bonecchi R, Polentarutti N, Luini W, et al. Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils. J Immunol 1999; 162: 474-479.
91. Lee SC, Brummet ME, Shahabuddin S, et al. Cutaneous injection of human subjects with macrophage inflammatory protein-1 alpha induces significant recruitment of neutrophils and monocytes. J Immunol 2000; 164: 3392-3401.
92. Cheng SS, Lai JJ, Lukacs NW, Kunkel SL. Granulocyte-macrophage colony stimulating factor up-regulates CCR1 in human neutrophils. J Immunot 2001; 166: 1178-1184.
93. Gerard C, Frossard JL, Bhatia M, et al. Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. J Clin Invest 1997; 100: 2022-2027.
94. Bhatia M, Proudfoot AE, Wells TNC, Christmas S, Neoptolemos JP, Slavin J. Treatment with Met-RANTES reduces lung injury in caerulein induced pancreatitis in mice. Br J Surg 2003; 90: 698-704.
95. Kobayashi M, Takahashi H, Sanford AP, Herndon DN, Pollard RB, Suzuki F. An increase in the susceptibility of burned patients to infectious complications due to impaired production of macrophage inflammatory protein 1 alpha. J Immunol 2002; 169: 4460-4466.
96. Hack CE, Hart M, van Schijndel RJ, et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992; 60: 2835-2842.
97. Rau B, Steinbach G, Gansauge F, Mayer JM, Grunert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997; 41: 832-840.
98. Shokuhi S, Bhatia M, Christmas S, Sutton R, Neoptolemos JP, Slavin J. Levels of the chemokines growth-related oncogene alpha and epithelial neutrophil-activating protein 78 are raised in patients with severe acute pancreatitis. Br J Surg 2002; 89: 566-572.
99. Brady M, Bhatia M, Christmas S, Boyd MT, Neoptolemos JP, Slavin J. Expression of the chemokines MCP-1/JE and cytokine-induced neutrophil chemoattractant in early acute pancreatitis. Pancreas 2002; 25: 260-269.
100. Bhatia M, Brady M, Zagorski J, et al. Treatment with neutralising antibody against cytokine induced neutrophil chemoattractant (CINC) protects rats against acute pancreatitis associated lung injury. Gut 2000; 47: 838-844.
101. Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J Clin Invest 2002; 110: 1703-1716.
102. Pallister I, Dent C, Topley N. Increased neutrophil migratory activity after major trauma: a factor in the etiology of acute respiratory distress syndrome? Crit Care Med 2002; 30: 1717-1721.
103. Adams JM, Hauser CJ, Adams CA Jr, et al. Entry of gut lymph into the circulation primes rat neutrophil respiratory burst in hemorrhagic shock. Crit Care Med 2001; 29: 2194-2198.
104. Abraham E, Carmody A, Shenkar R, Arcaroli J. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1137-L1145.
105. Tsokos M, Pufe T, Paulsen F, Anders S, Mentlein R. Pulmonary expression of vascular endothelial growth factor in sepsis. Arch Pathol Lab Med 2003; 127: 331-335.
106. Thickett DR, Armstrong L, Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med 2002; 166: 1332-1337.
107. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nature Med 2002; 8: 702-710.
108. Krein PM, Sabatini PJ, Tinmouth W, Green FH, Winston BW. Localization of insulin-like growth factor-I in lung tissues of patients with fibroproliferative acute respiratory distress syndrome. Am J Respir Crit Care Med 2003; 167: 83-90.
109. Maeda A, Hiyama K, Yamakido H, Ishioka S, Yamakido M. Increased expression of platelet-derived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest 1996; 109: 780-786.
110. Oswari J, Matthay MA, Margulies SS. Keratinocyte growth factor reduces alveolar epithelial susceptibility to in vitro mechanical deformation. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1068-L1077.
111. Welsh DA, Summer WR, Dobard EP, Nelson S, Mason CM. Keratinocyte growth factor prevents ventilator-induced lung injury in an ex vivo rat model. Am J Respir Crit Care Med 2000; 162: 1081-1086.
112. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol 2001; 280: C719-C741.
113. Modelska K, Matthay MA, Brown LA, et al. Inhibition of beta-adrenergic dependent alveolar epithelial clearance by oxidant mechanisms after hemorrhagic shock. Am J Physiol 1999; 276: L844-L857.
114. Hu P, Ischiropoulos JS, Beckman JS, et al. Peroxynitrite inhibition of oxygen consumption and sodium transport in alveolar type II cells. Am J Physiol 1994; 2: L628-L634.
115. Waters CM, Savla U, Panos RJ. KGF prevents hydrogen peroxide-induced increases in airway epithelial cell permeability. Am J Physiol 1997; 272: L681-L689.
116. Gutteridge JM, Mitchell J. Redox imbalance in the critically ill. Br Med Bull 1999; 55: 49-75.
117. Szabo C, Saunders C, O'Connor M. Salzman AI. Peroxynitrite causes energy depletion and increases permeability via activation of poly(ADP-ribose) synthetase in pulmonary epithelial cells. Am J Respir Cell Mol Biol 1997; 16: 107-109.
118. Wilson JN, Pierce JD, Clancy RL. Reactive oxygen species in acute respiratory distress syndrome. Heart Lung 2001; 30: 370-375.
119. Bernard GR, Lucht WD, Niedermeyer ME, et al. Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J Clin Invest 1984; 73: 1772-1784.
120. Seekamp A, Lalonde C, Deguang Z, et al. Catalase prevents prostanoid release and lung lipid peroxidation after endotoxemia in sheep. J Appl Physiol 1988; 65: 1210-1216.
121. Milligan SA, Hoeffel JM, Goldstein IM, et al. Effect of catalase on endotoxin induced acute lung injury in unanesthetized sheep. Am Rev Respir Dis 1988; 137: 420-428.
122. Amari T, Kubo K, Kobayashi T, et al. Effects of recombinant human superoxide dismutase on tumor necrosis factor-induced lung injury in awake sheep. J Appl Physiol 1993; 74: 2641-2648.
123. Gonzalez PK, Zhuang J, Doctorow SR, et al. EUK-8, a synthetic superoxide dismute and catalase mimetic, ameliorates acute lung injury in endotoxemic swine. J Pharmacol Exp Ther 1995; 275: 798-806.
124. Pittet JF, Lu IN, Morris DG, et al. Reactive nitrogen species inhibit alveolar epithelial fluid transport after hemorrhagic shock in rats. J Immunol 2001; 166: 6301-6310.
125. Arkovitz MS, Wispe JR, Garcia VF, et al. Selective inhibition of the inducible isoform of nitric oxide synthase prevents pulmonary transvascular flux during acute endotoxemia. J Pediatr Surg 1996; 31: 1009-1015.
126. Mathru M, Rooney MW, Dries DJ, et al. Urine hydrogen peroxide during adult respiratory distress syndrome in patients with and without sepsis. Chest 1994; 105: 232-236.
127. Keitzmann D, Kahl R, Muller M, et al. Hydrogen peroxide in expired breath condensate patients with acute respiratory failure and with ARDS. Intensive Care Med 1993; 19: 78-81.
128. Ouinlan GJ, Evans TW, Gutteridge JM. 4-Hydroxy-2. nonenal levels increase in the plasma of patients with adult respiratory distress syndrome as linoleic acid appears to fall. Free Rad Res 1994; 21: 95-106.
129. Roumen RM, Hendriks T, de Man BM, et al. Serum lipofuscin as a prognostic indicator of adult respiratory distress syndrome and multiple organ failure. Br J Surg 1994; 81: 1300-1305.
130. Lenz AG, Jorens PG, Meyer B, et al. Oxidatively modified proteins in bronchoalveolar lavage fluid of patients with ARDS and patients at risk for ARDS. Eur Respir J 1999; 13: 169-174.
131. Metnitz PG, Bartens C, Fischer M, et al. Antioxidant status in patients with acute respiratory distress syndrome. Intensive Care Med 1999; 25: 180-185.
132. Haddad IY, Pataki G, Hu P, et al. Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest 1994; 94: 2407-2413.
133. Sittipunt C, Steinberg KP, Ruzinski JT, et al. Nitric oxide and nitrotyrosine in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163: 503-510.
134. Zhu S, Ware LB, Geiser T, et al. Increased levels on nitrate and surfactant protein A nitration in pulmonary edema fluid of patients with acute lung injury. Am J Respir Crit Care Med 2001; 163: 166-172.
135. Walsh TS, Lee A. N-acetylcysteine administration in the critically ill. Intensive Care Med 1999; 25: 432-434.
136. Bernard GR, Wheeler AP, Arons MP, et al. The Antioxidant in ARDS Study Group: a trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 1997; 112: 164-172.
137. Gattinoni L, Bombino M, Pelosi P, et al. Lung structure and function in different stages of severe adult respiratory distress syndrome. J Am Med Assoc 1994; 271: 1772-1779.
138. Brigham KL, Stecenko AA. Gene therapy for acute lung injury. Intensive Care Med 2000; 26: s119-s123.
139. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998; 157: 1483-1488.
140. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide for the acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med 1998; 26: 15-23.
141. Vincent JL, Brase R, Santman F, et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med 2001; 27: 1578-1583.
142. Miesen WM, Ponssen HH, Jansen S, Posthuma RM, van Vliet AC. Aerosolized prostacyclin in acute respiratory distress syndrome caused by Chlamydiaceae spp. pneumonia. Neth J Med 2001; 59: 57-61.
143. Prewitt RM, Wood LDH. Effect of sodium nitroprusside on cardiovascular function and pulmonary shunt in canine oleic acid pulmonary edema. Anesthesiology 1981; 55: 537-541.
144. Bishop MJ, Kennard S, Artman LD, Cheney FW. Hydralazine does not inhibit canine hypoxic pulmonary vasoconstriction. Am Rev Respir Dis 1983; 128: 998-1001.
145. Radermacher B, Santak HJ, Wust J, Falke KJ. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology 1990; 72: 238-244.
146. Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med 2002; 30: 2175-2182.
147. Anzueto A, Baughman R, Guntupalli KK, et al. Aerosolized surfactants in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334: 1417 -1421.
148. Wiswell TE, Smith RM, Katz LB, et al. Bronchopulmonary segmental lavage with Surfaxin (KL-4-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160: 1188-1195.
149. Abraham E, Baughman R, Fletcher E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1999; 27: 1478-1485.
150. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912-918.
151. Luce JM, Montgomery AB, Marks JD, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138: 62-68.
152. Meduri GU, Headley AS, Golden E, et al. Effects of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. J Am Med Assoc 1998; 280: 159-165.
153. Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care 1999; 14: 1-6.
154. Hasegawa N, Oka Y, Nakayama M, et al. The effects of posttreatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs. Am J Respir Crit Care Med 1997; 155: 928-936.
155. Abraham E. Lisofylline versus placebo for ALI and ARDS. Am J Respir Crit Care Med 2000; 161: A379.
156. Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-436.
157. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 1-5.
158. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-742.
159. Reinhart K, Menges T, Gardlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES Study. Crit Care Med 2001; 29: 765-769.
160. Pittet D, Harbarth S, Suter PM, et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Am J Respir Crit Care Med 1999; 160: 852-857.
161. Balk R, Emerson T, Fourrier F, et al. Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Hemost 1998; 24: 183-194.
162. Moraes TJ, Chow CW, Downey GP. Proteases and lung injury. Crit Care Med 2003; 31: S189-S194.
163. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol 2002; 282: L924-L940.
164. Conary JT, Parker RE, Christman BW, et al. Protection of rabbit lungs from endotoxin injury by in vivo hyperexpression of the prostaglandin G/H synthase gene. J Clin Invest 1994; 93: 1834-1840.
165. Otterbein LE, Kolls JK, Mantell LL, et al. Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J Clin Invest 1999; 103: 1047-1054.
166. Nakao A, Fujii M, Matsumura R, et al. Transient gene transfer and expression of Smad 7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999; 104: 5-11.